Trial | Setting | Comparison | Efficacy | Safety | Comments |
---|---|---|---|---|---|
APPRAISE-240 | High-risk ACS within the previous 7 d, treated with ASA and clopidogrel | Apixaban 5 mg twice daily v. placebo | Cardiovascular death, MI or ischemic stroke: 7.5% v. 7.9% (HR 0.95, 95% CI 0.80–1.11) | Major bleeding:* 1.3% v. 0.5% (HR 2.59, 95% CI 1.50–4.46) |
|
ATLAS ACS 2–TIMI 5141 | ACS within the previous 7 d, treated with ASA and clopidogrel | Rivaroxaban 2.5 mg twice daily v. rivaroxaban 5.0 mg twice daily v. placebo | Cardiovascular death, MI or stroke: 2.5 mg twice daily v. placebo: 9.1% v. 10.7% (HR 0.84, 95% CI 0.72–0.97) 5.0 mg v. placebo: 8.8% v. 10.7% (HR 0.85, 95% CI 0.73–0.98) Cardiovascular death: 2.5 mg twice daily v. placebo: 2.7% v. 4.1% (HR 0.66, 95% CI 0.51–0.86) 5.0 mg v. placebo: 4.0% v. 4.1% (HR 0.94, 95% CI 0.75–1.20) | Non–CABG related major bleeding:* 2.5 mg twice daily v. placebo: 1.8% v. 0.6% (HR 3.46, 95% CI 2.08–5.77) 5.0 mg v. placebo: 2.4% v. 0.6% (HR 4.47, 95% CI 2.71–7.36) |
|
Note: ACS = acute coronary syndrome, APPRAISE-2 = Apixaban for Prevention of Acute Ischemic Events 2, ASA = acetylsalicylic acid, ATLAS ACS–TIMI = Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction, CABG = coronary artery bypass graft, CI = confidence interval, HR = hazard ratio, MI = myocardial infarction, TIMI = thrombolysis in myocardial infarction.
↵* As defined in TIMI trials (www.timi.org/wp-content/uploads/2010/10/TIMI-Definitions.pdf).